Luminex® 200 RUO System w/xPONENT 4.3 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemLuminex® 200 RUO System w/xPONENT 4.3
CompanyR&D Systems, a Bio-Techne Brand
Price Supplier Page View Company Product Page
Catalog NumberLX200-XPON-RUO
CompatibilityLuminex 200 Instrument
Quantity1 Kit
ApplicationsMultiplex Bioassays for Proteins and Nucleic Acids
Plate Formats96-well plate
Dynamic Range>3.5 logs

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) MIP-3-Alpha and MIP-3-Beta as Early Predictors of Pneumonia in Polytraumatized PatientsLungMarch 13, 2025Gregor Wollner, Florian Hruska, Paul Ettel, Thomas Weichhart, Felix R. M. Koenig, Lukas L. NegrinR&D Systems; Minneapolis, MN, USA) in conjunction with the Luminex® 200TM Instrument (Catalog no.: LX200-XPON-RUO; R&D Systems; Minneapolis, MN, USA). All measurements were conducted in duplicate, and mean values were

(2) Obesity alters the fitness of peritumoral adipose tissue, exacerbating tumor invasiveness in renal cancer through the induction of ADAM12 and CYP1B1Molecular OncologyJanuary 13, 2025Sepehr Torabinejad, Caterina Miro, Annarita Nappi, Francesco Del Giudice, Annunziata Gaetana Cicatiello, Serena Sagliocchi, Lucia Acampora, Federica Restolfer, Melania Murolo, Emery Di Cicco, et al.bead‐based multiplex assay was performed on a Luminex® 200™ System (Bio‐Techne, R&D Systems, Catalog Number: LX200‐XPON‐RUO). xPONENT software was utilized for the analysis of the results. 2.10 3D‐spheroid formation assay Multicellular

(3) Differences in Eotaxin Serum Levels between Polytraumatized Patients with and without Concomitant Traumatic Brain Injury-A Matched Pair AnalysisJournal of clinical medicineJuly 19, 2024Negrin LL, Ristl R, Wollner G, Hajdu S.no.: F CSTM18B-07; R&D Systems; Minneapolis, MN, USA) and the Luminex® 200™ Instrument (Catalog no.: LX200-XPON-RUO; R&D Systems; Minneapolis, MN, USA). All measurements were performed in duplicate, and mean values were

(4) Exploration of the induced cytokine responses in European Lyme neuroborreliosis: A longitudinal cohort studyTicks and tick-borne diseasesJanuary 1, 2023Gynthersen RMM, Ørbæk M, Mens H, Stenør C, Wiese L, Ostrowski SR, Nielsen SD, Lebech AM.

(5) Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary GroupClinical genitourinary cancerAugust 1, 2022García-Del-Muro X, Durán I, Perez-Gracia JL, Ángel Climent M, Mellado B, Virizuela JA, Castellano DE, González Del Alba A, García Carbonero I, Álvarez-Fernández C, et al.

(6) Plasma CD16⁺ Extracellular Vesicles Associate with Carotid Artery Intima-Media Thickness in HIV⁺ Adults on Combination Antiretroviral TherapymBioJune 28, 2022Marques de Menezes EG, Deng X, Liu J, Bowler SA, Shikuma CM, Stone M, Hunt PW, Ndhlovu LC, Norris PJ.

(7) Lipocalin 2 modulates dendritic cell activity and shapes immunity to influenza in a microbiome dependent mannerPLoS pathogensApril 1, 2021Watzenboeck ML, Drobits B, Zahalka S, Gorki AD, Farhat A, Quattrone F, Hladik A, Lakovits K, Richard GM, Lederer T, et al.

(8) HPV58 E7 Protein Expression Profile in Cervical Cancer and CIN with ImmunohistochemistryJournal of CancerJanuary 1, 2021Zheng Q, Chen X, Han R, Zhu J, Wang H, Chen L, Song Y, Chen L, Cheng H, Jin N.

(9) Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case reportNature communicationsDecember 14, 2020Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, Ogbe A, Zelek WM, Smielewska A, Yakovleva A, et al.

(10) Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor ModelsMolecular cancer therapeuticsApril 1, 2020Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S.

(11) Comparative analysis of abdominal fluid cytokine levels in ovarian hyperstimulation syndrome (OHSS)Journal of ovarian researchMarch 5, 2020Farkas B, Boldizsar F, Bohonyi N, Farkas N, Marczi S, Kovacs GL, Bodis J, Koppan M.

Be the First to Write a Review!